Biologics are a new class of drugs that fight disease at the source . Instead of attacking symptoms, these drugs target diseases like asthma at a molecular level. These newer types of drugs are more expensive than older medicines. That is prompting public discussion on how to pay for them. The cost of caring for patients with the most severe forms of asthma represents a majority of asthma healthcare spending. In addition, asthma is a leading cause of missed time from work and school. Last...
The Asthma and Allergy Foundation of America will recap some of the top research on allergies and asthma every quarter. Here is a look at studies reported between April and June 2017. Learn why some children may not respond to asthma treatments, how testosterone may affect asthma and more.
Hives, those annoying itchy red bumps, often occur with an allergic reaction or sometimes a viral infection. Or sometimes, they can be more serious when they happen with a severe allergic reaction called anaphylaxis.
AstraZeneca announced that the US Food and Drug Administration (FDA) approved SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms for the treatment of asthma in pediatric patients aged six up to 12 years.
[Press Release] Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of Asthma Approvals Expand Portfolio of Respiratory Medicines Delivered in RespiClick® Inhaler Designed to Eliminate the Need for Hand-Breath Coordination During Inhalation JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) approved two products for adolescent and adult patients with asthma.
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to intranasal corticosteroids.
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200
The Trump Administration released a final rule expanding the scope and applicability of association health plans (AHPs). The Department of Labor’s rule implements President Trump’s October 2017 executive order which directed agencies to change existing regulations to provide consumers with more options for health care coverage.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved QVAR® RediHaler™ (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older.
[Press Release] Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol First and Only Generic Fluticasone Propionate and Salmeterol (ICS/LABA) Inhaler Available in the U.S. JERUSALEM, April 20, 2017 – Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the simultaneous launch of AirDuo™ RespiClick® (fluticasone propionate and salmeterol) inhalation powder and its authorized generic for the treatment...
Do you suffer from hives? This week marks World Allergy Week, and the theme for this year’s event is The Agony of Hives - What to do when welts and swelling do not go away. The medical name for hives is urticaria. Hives are a common sign of an allergic reaction. Hives can also occur due to other causes, including a viral infection. Learn more by visiting Hives (Urticaria) . Find out when to call your health care provider, and when to go to the emergency room or call 911. Hives can occur due...
Novartis today announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily, DP2 receptor antagonist fevipiprant (QAW039). The pooled analyses of the LUSTER trials did not meet3 the clinically relevant threshold for reduction in rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses (150mg / 450 mg).
If you receive health insurance through your job, be sure to tell your employer now how important affordable, non-discriminatory health care is to you and your family! Many employers are shopping around for plans now before open enrollment begins in late fall.
The Asthma and Allergy Foundation of America (AAFA) conducts and promotes patient-centered research to help you. This means your beliefs, preferences and needs are at the center of our research. Your input drives our advocacy work, guides our education programs and supports our community. Recently, we’ve studied the following topics: Symptoms of anaphylaxis in infants and toddlers Eczema burdens and people’s experiences with treatments Impact of COVID-19 on people with asthma and allergy Air...
The U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent is the only biologic medicine approved for this patient population.
Novartis today announced that the US Food and Drug Administration (FDA) accepted the company's supplemental Biologics License Application (sBLA) for a new self-administration option for Xolair® (omalizumab) across all approved US indications. If approved, Xolair prefilled syringe would become available for either self-administration by select patients or administration by their caregivers.
When Diana Hanley’s daughter Jamie was a baby, she wheezed every time she got sick. She had her first allergic reaction to eggs at 11 months. Around age 2, she was diagnosed with a peanut allergy. And because of constant hives, many foods were removed from her diet. Her family is now part of research to help families managing asthma and allergies. Read Jamie's story.
Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection in appropriate patients across all approved US indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
The Asthma and Allergy Foundation of America (AAFA) is sharing this press release to bring you the latest research news quickly. [PRESS RELEASE] Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Children Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for...
FDA Expands Approval of DUPIXENT® (DUPILUMAB) to Include Children Ages 6 to 11 Years With Moderate-to-Severe Asthma. Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option.
*Sponsored by Merck Approximately 5% of adults in America are living with chronic cough, which is defined as a cough that lasts longer than 8 weeks. Patients with the condition commonly cough in “bouts” they cannot control, and usually feel a strong urge to cough before a coughing bout starts. Chronic cough is commonly associated with other health conditions, such as asthma, gastroesophageal reflux disease (GERD), upper airway cough syndrome and non-asthmatic eosinophilic bronchitis. It can...
Approximately 5% of adults in the U.S. are living with chronic cough, a cough that lasts longer than 8 weeks. People with the condition commonly cough in “bouts” they cannot control, and usually feel a strong urge to cough before a coughing bout starts.
When you block a person, they can no longer invite you to a private message or post to your profile wall. Replies and comments they make will be collapsed/hidden by default. Finally, you'll never receive email notifications about content they create or likes they designate for your content.
Note: if you proceed, you will no longer be following .